Product nameAnti-BTK (phospho Y551) antibody [EP267Y]
See all BTK primary antibodies
DescriptionRabbit monoclonal [EP267Y] to BTK (phospho Y551)
SpecificityThe antibody will detect BTK phosphorylation on Tyrosine 551.
Tested applicationsSuitable for: WB, ICCmore details
Unsuitable for: Flow Cyt,IHC or IP
Species reactivityReacts with: Human
Synthetic peptide within Human BTK. The exact sequence is proprietary.
- K562 cell lysate, Jurkat cell lysate (Pervanadate treated)
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.
This product is a recombinant rabbit monoclonal antibody.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferpH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 50% Glycerol, 0.05% BSA, 49% PBS
Concentration information loading...
Our Abpromise guarantee covers the use of ab40770 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/2000. Detects a band of approximately 74 kDa (predicted molecular weight: 74 kDa).|
|ICC||1/100 - 1/250.|
FunctionPlays a crucial role in B-cell ontogeny. Transiently phosphorylates GTF2I on tyrosine residues in response to B-cell receptor cross-linking. Required for the formation of functional ARID3A DNA-binding complexes.
Involvement in diseaseDefects in BTK are the cause of X-linked agammaglobulinemia (XLA) [MIM:300755]; also known as X-linked agammaglobulinemia type 1 (AGMX1) or immunodeficiency type 1 (IMD1). XLA is a humoral immunodeficiency disease which results in developmental defects in the maturation pathway of B-cells. Affected boys have normal levels of pre-B-cells in their bone marrow but virtually no circulating mature B-lymphocytes. This results in a lack of immunoglobulins of all classes and leads to recurrent bacterial infections like otitis, conjunctivitis, dermatitis, sinusitis in the first few years of life, or even some patients present overwhelming sepsis or meningitis, resulting in death in a few hours. Treatment in most cases is by infusion of intravenous immunoglobulin.
Defects in BTK may be the cause of X-linked hypogammaglobulinemia and isolated growth hormone deficiency (XLA-IGHD) [MIM:307200]; also known as agammaglobulinemia and isolated growth hormone deficiency or Fleisher syndrome or isolated growth hormone deficiency type 3 (IGHD3). In rare cases XLA is inherited together with isolated growth hormone deficiency (IGHD).
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. TEC subfamily.
Contains 1 Btk-type zinc finger.
Contains 1 PH domain.
Contains 1 protein kinase domain.
Contains 1 SH2 domain.
Contains 1 SH3 domain.
modificationsAutophosphorylated on Tyr-223 and Tyr-551. Phosphorylation of Tyr-223 may create a docking site for a SH2 containing protein.
Cellular localizationCytoplasm. Membrane. Nucleus.
- Information by UniProt
- Agammaglobulinaemia tyrosine kinase antibody
- AGMX 1 antibody
- AGMX1 antibody
All lanes : Anti-BTK (phospho Y551) antibody [EP267Y] (ab40770) at 1/5000 dilution
Lane 1 : Ramos (human Burkitt's lymphoma) treated with Pervanadate whole cell lysates
The treatment protocols were not recorded.
Lane 2 : Untreated Ramos (human Burkitt's lymphoma) whole cell lysates
Lysates/proteins at 10 µg per lane.
All lanes : Goat Anti-Rabbit IgG, (H+L), HRP conjugated at 1/1000 dilution
Predicted band size: 74 kDa
Observed band size: 74 kDa
Exposure time: 30 seconds
Blocking/Diluting buffer 5% NFDM/TBST
This product has been referenced in:
- Mo ZQ et al. Molecular characterization and function analysis of grouper (Epinephelus coioides) Bruton's tyrosine kinase BTK. Fish Shellfish Immunol 77:91-99 (2018). WB . Read more (PubMed: 29567142) »
- Rushworth SA et al. Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia. Blood 123:1229-38 (2014). Human . Read more (PubMed: 24307721) »